Bioengineers at The University of Texas at Dallas have created a novel gene-delivery system that shuttles a gene into a cell, but only for a temporary stay, providing a potential new gene-therapy strategy for treating disease.
The approach offers distinct advantages over other types of gene therapies under investigation, said Richard Taplin Moore MS’11, a doctoral student in bioengineering in the Erik Jonsson School of Engineering and Computer Science. He is lead author of a study describing the new technique in the Jan. 30 issue of the journal Nucleic Acids Research.
“In other gene therapy approaches, the therapeutic genetic messages being delivered can persist for a long time in the patient, potentially lasting for the patient’s entire lifetime,” Moore said. “This irreversibility is one reason gene therapies are so difficult to get approved.”
The UT Dallas study describes proof-of-concept experiments in which a gene carrying instructions for making a particular protein is ordered to self-destruct once the cell has “read” the instructions and made a certain quantity of the protein. In its experiments with isolated human kidney cells, the research team successfully delivered — and then destroyed — a test gene that makes a red fluorescent protein.
More research is needed to determine whether and how well the system might work in living organisms. But Moore said the ultimate goal is to refine the method to deliver genes that produce therapeutic proteins or drugs. The nature of the gene delivery system offers more control over how much protein the gene produces in cells or tissues. Because it does not alter the cell permanently, the method also sidesteps potential health problems that can occur if a gene is delivered to the wrong place in a cell’s genome.
“Our goal was to create a delivery system for therapeutic genes that would self-destruct, giving us more control over the delivered DNA by limiting the time it resides in cells,” Moore said.
Read more: Team Creates New Approach to Gene Therapy
The Latest on: Gene Therapy
via Google News
The Latest on: Gene Therapy
- Biogen to invest $200M in new gene therapy manufacturing facilityon March 4, 2021 at 6:09 am
One of Massachusetts' largest biotech firms is planning to grow its already-large presence in North Carolina's Research Triangle with a $200 million investment it says will create scores of jobs.
- Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in ...on March 3, 2021 at 8:52 pm
The innovative and scalable gene therapy manufacturing facility will support Biogen’s plan to advance its gene therapy portfolio; The new facility is expected to employ approxim ...
- OXGENE Eyes Further Growth in Cell and Gene Therapy Services after Acquisition by WuXi AppTecon March 3, 2021 at 6:04 am
WuXi AppTec has acquired British contract R&D services provider OXGENE for $135 million. The deal gives the Shanghai-based biopharma its first European facility and broadens its portfolio of ...
- Global Cancer Gene Therapy Market Size 2021, Share, Growth, Industry Analysis and Future Demand, Top Key Players and Forecast 2026on March 3, 2021 at 2:02 am
Cancer Gene Therapy Market “(2021-2025)The Cancer Gene Therapy market is expected to grow from USD million in 2021 to ...
- Tips to Ensure Product Comparability in Gene Therapyon March 3, 2021 at 12:00 am
Studying how manufacturing process changes affect product quality is a critical issue in the development of novel gene therapies.
- Innovative neurosurgical technique used in Tay-Sachs gene therapy clinical trialon March 2, 2021 at 2:32 pm
Oguz Cataltepe, MD, describes the innovative neurosurgical procedure used to treat patients in the new clinical trial for a gene therapy targeting infantile Tay-Sachs and Sandhoff diseases.
- Overcoming the gene therapy manufacturing bottleneckon March 1, 2021 at 4:00 pm
In the early days of genetic engineering, scientists predicted gene therapies that would treat, or even cure, inherited disease by inserting a healthy gene into a patient’s cells to replace a ...
- Gene therapy 3.0? Gene-coding startup launches with $20Mon March 1, 2021 at 5:00 am
A new biotech is emerging from stealth to develop what its CEO calls "third-generation gene therapy." Founded by former Human Genome Project researcher Joseph Higgins, SalioGen Therapeutics launched ...
- 8 gene-therapy upstarts that could be M&A targets as biotech veterans like Bluebird face safety questionson February 27, 2021 at 1:16 am
A handful of gene therapy companies have run into potential safety issues. Analysts say this could spur deals with startups developing new tools.
- Global Gene Therapy Market: Comprehensive Study, Application, Top Companies , Regional Insights and COVID-19 Impact Analysison February 26, 2021 at 10:11 am
Global Gene Therapy Market is valued at USD 1.5 billion in 2020 which is expected to reach USD 6.8 billion by 2027 at a ...
via Bing News